Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women. A double-blind randomised clinical trial.

@article{Knapen2015Menaquinone7SI,
  title={Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women. A double-blind randomised clinical trial.},
  author={Marjo H. J. Knapen and Lavienja Braam and Nadja E. A. Drummen and Otto Bekers and Arnold P.G. Hoeks and Cees Vermeer},
  journal={Thrombosis and haemostasis},
  year={2015},
  volume={113 5},
  pages={
          1135-44
        }
}
Observational data suggest a link between menaquinone (MK, vitamin K2) intake and cardiovascular (CV) health. [...] Key Method Healthy postmenopausal women (n=244) received either placebo (n=124) or MK-7 (n=120) for three years. Indices of local carotid stiffness (intima-media thickness IMT, Diameter end-diastole and Distension) were measured by echotracking. Regional aortic stiffness (carotid-femoral and carotid-radial Pulse Wave Velocity, cfPWV and crPWV, respectively) was measured using mechanotransducers…Expand
Impact of menaquinone-4 supplementation on coronary artery calcification and arterial stiffness: an open label single arm study
TLDR
The benefits of MK-4 supplementation were only observed in patients with vitamin K insufficiencies correlated with high PIVKA-2 baseline levels, reducing baPWV but not CAC, and despite high dose MK- 4 supplementation, CAC increased +14 % annually, but baPV did not change (−0.7 %).
Menaquinone-7 Supplementation to Reduce Vascular Calcification in Patients with Coronary Artery Disease: Rationale and Study Protocol (VitaK-CAC Trial)
TLDR
The VitaK-CAC trial is a doubleblind, randomized, placebo-controlled trial which analyses effects of menaquinone-7 (MK-7) supplementation on progression of CAC and hypothesize that treatment with MK-7 will slow down or arrest the progression ofCAC and that this trial may lead to a treatment option for vascular calcification and subsequent CVD.
The effect of menaquinone-7 supplementation on vascular calcification in patients with diabetes: a randomized, double-blind, placebo-controlled trial
TLDR
MK-7 supplementation tended to increase active calcification measured with 18F-NaF PET activity compared with placebo, but no effect was found on conventional CT.
Vitamin K supplementation and arterial calcification in dialysis: results of the double-blind, randomized, placebo-controlled RenaKvit trial
TLDR
Vitamin K supplementation improved vitamin K status, but did not hinder or modify the progression of arterial calcification in dialysis patients.
Vitamin K2 supplementation and arterial stiffness among renal transplant recipients-a single-arm, single-center clinical trial.
TLDR
Among renal transplant recipients with stable graft function, vitamin K2 supplementation was associated with improvement in subclinical vitamin K deficiency and arterial stiffness.
Vitamin K Supplementation to Improve Vascular Stiffness in CKD: The K4Kidneys Randomized Controlled Trial.
TLDR
Vitamin K2 supplementation did not improve arterial stiffness or other measures of vascular health in this trial involving individuals with CKD, and a recently published meta-analysis showed no effect of vitamin K supplementation on vascular stiffness or vascular calcification measures.
Effects of menaquinone-7 supplementation in patients with aortic valve calcification: study protocol for a randomised controlled trial
TLDR
It is hypothesised that MK-7 supplementation will slow down the calcification process of aortic valve calcification and result in difference in AVC score from baseline to follow-up at 2 years.
Inactive Matrix Gla-Protein Is Associated With Arterial Stiffness in an Adult Population–Based Study
TLDR
High levels of dp-ucMGP are independently and positively associated with arterial stiffness after adjustment for common cardiovascular risk factors, renal function, and age.
Glycemic control improvement in individuals with type 2 diabetes with vitamin K2 supplementation: a randomized controlled trial
TLDR
Daily intake of 360 µg Vitamin K2 in the form of MK-7 for 12-weeks reduces FPG and HbA1c in patients with T2DM but does not have a lipid-lowering effect.
The ViKTORIES trial: A randomized, double‐blind, placebo‐controlled trial of vitamin K supplementation to improve vascular health in kidney transplant recipients
  • J. Lees, A. Rankin, +9 authors P. Mark
  • Medicine
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2021
TLDR
In this heterogeneous cohort of prevalent KTR, vitamin K supplementation did not reduce vascular stiffness or calcification over 1 year, and Improving vascular health in KTR is likely to require a multifaceted approach.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 53 REFERENCES
Vitamin K supplementation and progression of coronary artery calcium in older men and women.
TLDR
Phylloquinone supplementation slows the progression of CAC in healthy older adults with preexisting CAC, independent of its effect on total MGP concentrations.
Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study.
TLDR
It is suggested that an adequate intake of menaquinone could be important for CHD prevention and not related to any of the outcomes.
High dietary menaquinone intake is associated with reduced coronary calcification.
TLDR
It is shown that high dietary menaquinone intake, but probably not phylloquinone, is associated with reduced coronary calcification and could therefore be important to prevent cardiovascular disease.
Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial.
TLDR
This is the first study showing that inactive MGP levels can be decreased markedly by daily vitamin K(2) supplementation, and provides the rationale for intervention trials aimed at decreasing vascular calcification in hemodialysis patients by vitamin K supplementation.
Low-dose menaquinone-7 supplementation improved extra-hepatic vitamin K status, but had no effect on thrombin generation in healthy subjects
TLDR
MK-7 supplementation at doses in the order of the RDA (Commission Directive 2008/100/EC) increased the carboxylation of circulating OC and MGP, and no adverse effects on thrombin generation were observed.
A high menaquinone intake reduces the incidence of coronary heart disease.
TLDR
A high intake of menoquinones, especially MK-7, MK-8 and MK-9, could protect against CHD, however, more research is necessary to define optimal intake levels of vitamin K intake for the prevention of CHD.
Beneficial effects of vitamins D and K on the elastic properties of the vessel wall in postmenopausal women: a follow-up study.
TLDR
It is concluded that a supplement containing vitamins K1 and D has a beneficial effect on the elastic properties of the arterial vessel wall.
Circulating uncarboxylated matrix gla protein is associated with vitamin K nutritional status, but not coronary artery calcium, in older adults.
TLDR
Plasma ucMGP was associated with vitamin K status biomarkers and was reduced following phylloquinone supplementation, suggesting it may be a useful marker of vitamin Kstatus in vascular tissue in healthy older adults.
Six weeks phylloquinone supplementation produces undesirable effects on blood lipids with no changes in inflammatory and fibrinolytic markers in postmenopausal women
TLDR
Six weeks supplementation with a dose of phylloquinone similar to that obtainable from the diet induced a deterioration of the lipid profile with no improvement in any of the other risk markers analysed, suggesting that results do not support a cardioprotective effect of vitamin K.
Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women
TLDR
MK-7 supplements may help postmenopausal women to prevent bone loss and be extended to other populations, e.g., children and men, because of the longer half-life and greater potency of the long-chain MK-7.
...
1
2
3
4
5
...